Study S001964

WEgovy Real World Assessment of Weight Loss in Korea (WE-WALK): a Multi-centre, Prospective, Single-arm, Nonintervention Study to Investigate the Effectiveness and Safety of Once-weekly Semaglutide 2.4 mg for People Living With Obesity in Routine Clinical Practice in Korea

ClinicalTrials.gov record

Registration

Registration: NCT07280221
Study type: OBSERVATIONAL
Status: ENROLLING_BY_INVITATION
Enrollment: 500
Start: 2025-11-10
Primary completion: 2027-10-31
Lead sponsor: Novo Nordisk A/S
Conditions: Obesity
Interventions: DRUG:Semaglutide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1306-1595

Registered primary outcomes

Percentage change in body weight [From baseline (week 0) to 24 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.